2

2 Cited Publications

Target:

Research Areas:

Caloxin 2A1 is an extracellular plasma membrane Ca ²⁺-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal Mg ²⁺-ATPase or Na ⁺-K ⁺-ATPase .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

Caloxin 2A1 TFA

2 Cited Publications

Cat. No.: HY-P3278A

Target:

Proton Pump

Research Areas:

Metabolic Disease

Caloxin 2A1 TFA is an extracellular plasma membrane Ca ²⁺-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg ²⁺-ATPase or Na ⁺-K ⁺-ATPase .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Calotatug ginistinag

Cat. No.: HY-164919

CAS No.: 2847102-44-5

Synonyms: XMT-2056

Target:

Antibody-Drug Conjugates (ADCs) EGFR STING IFNAR TNF Receptor Interleukin Related CXCR

Research Areas:

Inflammation/Immunology Cancer

Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate (ADC) targeting HER2, linked to a payload composed of XMT-1519 conjugate-1 (HY-148067) and STING agonist-20 (HY-148068). Calotatug ginistinag activates the STING signaling pathway in tumor cells and tumor-resident immune cells, induces the production of type I interferons and cytokines (CXCL10, IFN-β, IL-6, TNF-α, triggers innate anti-tumor immune responses, and exerts a bystander effect. Calotatug ginistinag exhibits efficacy against HER2-expressing cancer cells in co-culture with PBMCs. Calotatug ginistinag induces tumor regression and reduces systemic inflammation in various tumor models. Combination treatment with Calotatug ginistinag, Trastuzumab (HY-P9907) and T-DXd (HY-138298) yields benefits. Calotatug ginistinag can be used in studies related to HER2-expressing solid tumors such as breast cancer, gastric cancer and ovarian cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Caloxin 1b3

Cat. No.: HY-P11292

Target:

Calcium Channel

Research Areas:

Cardiovascular Disease

Caloxin 1b3, a peptide, is a selective plasma membrane Ca ²⁺ pump 1 (PMCA1) inhibitor. Caloxin 1b3 significantly inhibits PMCA1 Ca ²⁺–Mg ²⁺-ATPase in the rabbit duodenal mucosa than the PMCA4 in the human erythrocyte ghosts. Caloxin 1b3 also increases cytosolic Ca ²⁺ concentration in endothelial cells. Caloxin 1b3 can be used for cardiovascular disorders research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Caloxin 1C2

Cat. No.: HY-P10655

Target:

Proton Pump Calcium Channel

Research Areas:

Cardiovascular Disease

Caloxin 1C2 is a specific PMCA (plasma-membrane Ca ²⁺-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The K_i values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca ²⁺ transfer. Caloxin 1C2 affects coronary contractility .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Caloxin 1B1

Cat. No.: HY-P5421

CAS No.: 898221-46-0

Target:

Proton Pump

Research Areas:

Others

Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Caloxin 3A1

Cat. No.: HY-P5422

Target:

Calcium Channel

Research Areas:

Others

Caloxin 3A1 is a biological active peptide. (This peptide belongs to caloxins, the extracellular plasma membrane (PM) Ca2+ pump inhibitors. Caloxin 3A1 inhibits plasma membrane calcium pumps (PMCAs) but not the sarcoplasmic reticulum Ca2+-pump. This peptide does not inhibit formation of the acylphosphate intermediate from ATP.)

Compare

loading...